Fig. 6
(Reproduced with permission from [156]. © 2021 by Ana Luiza C. de S.L.Oliveira et al.)
Folic acid modification of PLGA NPs containing oxaliplatin enhances its targeting and antitumor capacity. a Schematic of the formulation of PLGA-PEG-FA NPs; b: analysis of cell binding and uptake of NPs under fluorescence microscopy after incubation of PLGA-PEG and PLGA-PEG-FA NPs on CT26 cells for different times; c changes in tumor volume and weight of CT26 tumor-bearing mice under different treatment groups